EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Duvakitug was well tolerated and safety was consistent with the induction study
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Subscribe To Our Newsletter & Stay Updated